Latest news with #MET
CTV News
2 days ago
- General
- CTV News
Small plane crash at Montreal South Shore airport causes no injuries
The Saint-Hubert airport. (CNW Group/Porter Airlines Inc.) A small plane crashed at the Montreal Metropolitan Airport (MET), in the Saint-Hubert borough of Longueuil, Saturday. The crash occurred on the runway on Saturday afternoon, shortly before 1 p.m. Few details were available, but assistance from Longueuil police (SPAL) and firefighters was requested. Two men, aged 45 and 21, were on board the aircraft. 'According to the information available at this time, no injuries required hospital attention,' said SPAL Sergeant Marie Beaudet. The two men were scared but unharmed, he said. Airport operations later on Saturday. This report by The Canadian Press was first published in French June 8, 2025.
Daily Mirror
03-06-2025
- Daily Mirror
Good Morning Britain's Susanna Reid cuts to co-star for Madeleine McCann update
Good Morning Britain was hosted by Susanna Reid and Ed Balls on Tuesday's episode Susanna Reid swiftly handed over to her colleague for a major development in the Madeleine McCann case on Tuesday's episode of Good Morning Britain. The 54-year-old presenter passed the baton to Good Morning Britain's Chief Correspondent Richard Gaisford, who was live from Portugal with the latest developments. Richard updated viewers that approximately 30 German police officers, including forensics experts, are set to start an intensive search in Portugal this morning. They have identified an area between the hotel where the McCann family was staying and a property connected to a suspect in the case, Christian Brueckner. At the beginning of Tuesday's show, Susanna moved quickly to connect with Richard who was onsite in Portugal to discuss the fresh updates. Susanna asked Richard: "Richard, it's all about to begin again. Are the police acting on new information do you know?", reports Bristol Live. Richard replied: "Well that's what we don't know, but as you've already reported Susanna they are here in force and ready to start what is an extensive search." He continued: "I've just been speaking with the Portuguese police officers who are guarding this particular scene just outside. Telling me they're expecting this search to start here in the next hour or two. "German police have applied for a European investigation order, they will arrive here at the scene with a judicial warrant. The land owner can do nothing about that but sit back and watch and see what develops. "They are looking at land associated in some way with Christian Brueckner, who the German police believe is the prime suspect in the disappearance of Madeleine McCann. "He is currently in jail in Germany, that is in relation to the rape of an elderly woman in Praia da Luz. He was living in Praia da Luz or around Praia da Luz at the time that Madeleine disappeared 18 years ago. "They will be looking at land close to the house, just a half a km or km outside Praia da Luz that he rented - other areas around the area too as well. "Metropolitan police telling us they're not involved in this but they will give support if required. Remember, they have been here in large numbers searching over the last 18 years. "Interestingly, Susanna and Ed, the MET has just been given another £100,000 by the government to continue the search for Madeleine McCann which is still very much in people's minds. We will see over the next few days what develops."
Business Wire
02-06-2025
- Business
- Business Wire
MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg ® (MaaT013) in Acute Graft-versus-Host Disease
LYON, France--(BUSINESS WIRE)--Regulatory News: 'Submitting our MAA to the EMA marks a major regulatory milestone for MaaT Pharma and a meaningful advancement for patients with refractory aGvHD—a life-threatening complication of stem cell transplantation with no approved therapies" Share MaaT Pharma (EURONEXT: MAAT – the 'Company'), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced the submission of the Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its lead drug candidate MaaT013, under the registered brand name of Xervyteg ®. If approved, the Marketing Authorization would establish Xervyteg ® as the first microbiota therapeutic approved by the EMA, and the first one globally for a hematology indication. Xervyteg ® would also be the first approved therapy for the treatment of acute Graft-versus-Host Disease including gastro-intestinal involvement (GI-aGvHD) following 2 prior lines of systemic therapy. 'Submitting our MAA to the EMA marks a major regulatory milestone for MaaT Pharma and a meaningful advancement for patients with refractory aGvHD—a life-threatening complication of stem cell transplantation with no approved therapies,' said Hervé Affagard, Co-founder and CEO of MaaT Pharma. 'We are now closer to providing a much-needed treatment option and remain deeply committed to advancing immunomodulating microbiota technologies in hemato-oncology, where new solutions are urgently needed.' While advancing toward the commercialization of Xervyteg ® (if approved) in Europe, MaaT Pharma is also actively exploring strategic partnerships to ensure broad access in timely fashion. The Company has active discussions with experienced partners who share its mission of delivering meaningful advancements to patients. In parallel to the MAA submission, MaaT Pharma continues to provide access to Xervyteg ® in Europe and the U.S. through its Early Access Program (EAP) 1 for patients with aGvHD and other indications. In 2024, physician demand for Xervyteg ® under the EAP (n=107) increased by 75% compared to 2023, driven by growing adoption across Europe and in the U.S. In France where the EAP first started, MaaT Pharma has captured 25% of the addressable market on a yearly basis in 2024. Overall, this position reflects the increasing recognition of Xervyteg ® as a valuable treatment option for GI-aGvHD patients. aGvHD is the most severe complication of allogeneic stem cell transplantation, a standard-of-care treatment with curative intent offered to patients with blood cancers and some non-malignant hematological conditions. aGvHD refractoriness to current treatments is frequently encountered and severely impacts prognosis. In particular, patients with aGvHD failing both steroid and ruxolitinib typically exhibit a dismal prognosis, with a median survival of 28 days and 85% mortality at one year (Abedin et al 2021). Currently, no therapy is approved for third-line aGvHD, underscoring the urgent need for innovative therapies capable of improving survival and quality of life. The MAA is supported by positive results from the Pivotal ARES study, a single-arm, open-label, multicenter European study evaluating the efficacy and safety of Xervyteg ® in GI-aGvHD as third-line therapy in 66 patients. Notably, the study met its primary endpoint, achieving a gastrointestinal overall response rate (GI-ORR) of 62% at Day 28, significantly exceeding the expected 38% response rate, and an overall response rate across all organs of 64% at Day 28. Among responding patients at Day 28, the majority exhibited full resolution of GvHD clinical manifestations (i.e., complete response), an important finding predictive of durable control of aGvHD clinical manifestations over time. The 12-month probability of survival was 54% (vs 15% Abedin et al, 2021). Importantly, patients who exhibited gastrointestinal response at Day 28 had a significantly better probability of survival than non-responders (67% vs 28% respectively, p <0.0001), indicating that Xervyteg ® -mediated aGvHD control is associated with a remarkable survival benefit. Additional secondary endpoints, including overall survival, will become available in late H2 2025. The Company also integrated supporting safety and efficacy data from 186 aGvHD patients 2 treated under its ongoing EAP, which aligns with the positive topline results of the ARES trial and further supports Xervyteg ® 's strong efficacy and favorable safety profile in aGvHD. The safety and tolerability of Xervyteg ® has been monitored by an independent Data Safety Monitoring Board (DSMB). In March 2025, the DSMB reviewed the overall safety of the trial (after all patients completed Day 28 visit or were discontinued earlier) and confirmed that 'given the remarkable efficacy results, the study results show an acceptable safety profile and a favourable benefit /risk ratio'. The DSMB members will continue to review safety on an ongoing basis until the 1-year follow-up. The EMA will review the application under the centralized marketing authorization procedure and potentially a marketing authorization could be granted in H2 2026. This centralized procedure means that a single marketing authorization application can be submitted to the EU, and if granted by the European Commission, the authorization is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway. About acute Graft-versus-Host Disease Acute Graft-versus-Host Disease occurs in patients within 100 days of undergoing a stem cell or bone marrow transplant, where the transplanted cells initiate an immune response and attack the transplant recipient's organs, causing inflammation of the skin, liver and/or gastro-intestinal tract and leading to significant morbidity and mortality. GI involvement is associated with severe complications such as profound diarrhea, abdominal pain, intestinal bleeding, and death. These complications are often life-threatening, with increased mortality risk, due to the challenges of managing severe GI inflammation and the associated risks of infection, malnutrition, and organ failure. The standard first line therapy for treating aGvHD is the use of systemic steroids. If patients do not respond to steroids, they are considered Steroid Resistant (SR) and other agents can be administered. Currently the only agent approved for treating SR aGvHD after failure of steroid treatment is ruxolitinib, which is currently approved for this indication in USA and has received approval from the European Medical Agency's Committee for Human Medicinal Products (CHMP) on March 25, 2022. About Xervyteg ® (MaaT013) MaaT Pharma's Microbiome Ecosystem Therapies (MET) are designed to leverage a full microbiome ecosystem to restore balance and maximize clinical benefits for patients with severe, treatment-induced dysbiosis in acute diseases. Xervyteg ® (MaaT013) is a full-ecosystem, off-the-shelf, standardized, pooled-donors, enema Microbiome Ecosystem Therapy TM for acute, hospital use. It is characterized by a consistently high diversity and richness of microbial species and the presence of Butycore TM (a group of bacterial species known to produce anti-inflammatory metabolites). Xervyteg ® (MaaT013) aims to restore the symbiotic relationship between the patient's functional gut microbiome and their immune system to correct the responsiveness and tolerance of immune functions and thus reduce steroid-resistant, gastrointestinal (GI)-aGvHD. Xervyteg ® (MaaT013) has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). About MaaT Pharma MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021. Forward-looking Statements All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as 'target,' 'believe,' 'expect,' 'aim', 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. presented at the EHA Annual Congress 2 The cutoff date was October 3, 2024
Fashion Value Chain
02-06-2025
- Science
- Fashion Value Chain
MRV Celebrates Academic Excellence
At MET Rishikul Vidyalaya (MRV), Bandra, academic brilliance is a tradition nurtured through a global curriculum, innovative teaching, and a focus on holistic development. In the March 2025 Cambridge IGCSE and AS & A Level examinations, MRV students have once again made the school proud with their exceptional results. Mr. Pankaj Bhujbal, Hon. Trustee, MET with IGCSE 2024-25 batch & A Level 2023-25 batch students celebrating achievements of school and subject toppers The Cambridge IGCSE (Class 10) batch of 49 students achieved a 100% pass rate, with 87 A* and 82 A grades. Leading the cohort is Jash Nagrecha with an impressive 92.71%, followed by Anshul Khandeparkar with 92%, Pranav Hinduja with 91.28%, Avneesh Kane with 90% & Devansh Deshmukh with 89.42%. Vihaan Sinyal achieved a near-perfect 99% in Mathematics (without coursework), Jash also topped in Chemistry (98%), Biology (95%), Business Studies (93%), English (89%), and Literature (86%). Anshul stood out with 95% in Accounting and 94% each in ICT and Economics. Hitansh Shah excelled in Physics (95%), Avneeh Kane in French (95%), and Rajveer Shah in Hindi (91%). Pranav Hinduja led in Global Perspectives (90%), Devansh Deshmukh in Computer Science (93%), and Sharwill Nilakh in Art and Design (88%). In AS & A Levels, the 44 student batch secured 8 A* and 21 A grades. Jeena Tolani topped with 94%, followed by Aditya Chitre at 91% and Shruti D'Silva at 82.66%. Jeena also achieved 95% in Accounting, 94% in Mathematics, 93% in Business, and 90% in Economics. Hriday Shah scored 93% in Business, while Aditya earned 93% in Chemistry and 92% in Physics. Aaliya Panjwani topped Psychology with 91%, while Ishwari Arjunwadkar, Shruti D'Silva, and Muskaan Shah scored 80% in Biology. Ishwari also achieved 86% in the English General Paper, and Ethan Costa scored 80% in English Language. Reflecting on the results, Shri Pankaj Bhujbal, Hon. Trustee, MET, shared, 'These outstanding results reflect MRV's commitment to academic excellence and global readiness. Our students continue to make us proud with their discipline, curiosity, and dedication.' At MRV, academic achievement is one of the many ways students are prepared for success in a complex, ever-evolving world. With a focus on personalized learning, global exposure, and values-based education, MRV students are equipped not only to excel in examinations but also to lead with integrity, empathy, and purpose.
News18
01-06-2025
- Entertainment
- News18
Priyanka Chopra Holds Nick Jonas Close, Singer Kisses Her Shoulder In Hot MET Gala Pics
Last Updated: Priyanka Chopra shared MET Gala 2025 photos, showing glamorous outfits, moments with Nick Jonas, and a cute shot of their daughter Malti Marie. Priyanka Chopra just dropped a swoon-worthy behind-the-scenes photo dump from her MET Gala 2025 weekend—and it's serving glamour, romance, and a dash of adorable! The carousel begins with a striking solo shot: Priyanka stuns in her MET ensemble – a white halter-neck column gown adorned with bold black polka dots, cinched at the waist with a slim belt. Channeling vintage Hollywood elegance, she completed the look with dramatic elbow-length black gloves, a statement emerald necklace, and a larger-than-life black hat. Her caption? Simple yet swoony: 'Still thinking about this date night.. #MET25" — paired with the smooth jazz notes of Dave Brubeck's Take Five playing in the background. Another photo raises the temperature—Priyanka shares a sultry moment with husband Nick Jonas. The couple is seen in a moody, golden-lit room, standing close by a mirror. Priyanka wears a sparkly silver fringe mini-dress, while Nick looks sharp in a tailored suit. Their intense eye contact and Nick's protective hand placement speak volumes—clearly, date night was a whole vibe. In another photo, Nick gently kisses her shoulder. But it's the third image that stole hearts: little Malti Marie making her hallway runway debut in a red frock, black gloves, white socks—and yes, rocking her mom's oversized MET Gala hat. Shot from behind, the photo is pure joy, showing how fashion clearly runs in the family. Check out the photos here: The Met Gala is a special chapter in Priyanka Chopra and Nick Jonas's love story, as they first attended the event together in 2017 before starting their relationship. After missing last year's gala, the couple returned to the blue carpet for the 2025 event. For the occasion, Priyanka turned heads in a unique polka dot jacket, matching dress and a flowing train, while Nick looked charming in a black and white outfit. On the work front, Priyanka Chopra is all set to return to Indian cinema with SS Rajamouli's upcoming film starring Mahesh Babu. She has already shot crucial scenes in locations across Odisha and Hyderabad. First Published:
